Sammanfattning
The tumour micro-environment has emerged as an essential component in B-cell non-Hodgkin lymphoma pathology, with both nurturing and protective cells. The diversity and impact of the micro-environment seems to be greater in the indolent lymphoma types, while the aggressive subtypes are more independent. The prognostic impact of the environmental cells seems to depend on the specific treatment, and novel treatments targeting the micro-environment are emerging. Immune checkpoints, expressed by lymphomas, serve as promising targets for immune checkpoint inhibitors and vaccination therapy.